Kenneth C. Lim

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management.

Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management.

Journal: Alimentary pharmacology & therapeutics

Published: July 02, 2026

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

Journal: American journal of hematology

Published: March 31, 2026

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

Journal: British journal of haematology

Published: March 16, 2026

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Journal: Blood advances

Published: November 18, 2025

Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.

Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.

Journal: Blood advances

Published: October 23, 2025

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 11, 2025

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma.

Journal: Blood cancer journal

Published: August 26, 2025

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma.

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 28, 2025

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Journal: Journal of the National Cancer Institute

Published: January 07, 2025

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 05, 2024

Real-world utility of cytogenetic testing in cases with 'suspected myelodysplastic neoplasm but insufficient morphological features for diagnosis': a Victorian Cancer Cytogenetics Service experience.

Real-world utility of cytogenetic testing in cases with 'suspected myelodysplastic neoplasm but insufficient morphological features for diagnosis': a Victorian Cancer Cytogenetics Service experience.

Journal: Pathology

Published: May 21, 2024

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

Journal: The Lancet. Haematology

Published: October 07, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026